Varicela e herpes-zóster
Palavras-chave:
zóster, varicela, nevralgia pós-herpéticaResumo
A infecção pelo vírus varicela-zóster é a doença mais prevalente no mundo, afetando 95% da população adulta. Sua manifestação mais agressiva é o herpes-zóster, que afeta primariamente adultos e imunossuprimidos. O tratamento é efetivo com o aciclovir e fármacos derivados como o valaciclovir e famciclovir. Novas vacinas como a Zostavax e a Shingrix, recém-aprovadas em nosso país, são armas importantes na prevenção do zóster e da sua principal complicação, a nevralgia pós-herpética.
Referências
Alper BS, Lewis, PR. Treatment of posherpetic neuralgia: a systematic review of the literature. J. Fam. Pract. 2002; 51- 121-8.
Carter GT, Galer BS. Advances in the management of neurophatic pain. Phys. Med. Rehabil. Clin. N. Am. May/2001; 12(2)-447-59.
Cunningham AL et al. 2016. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 375:1019-32.
Davies SJ. A novel treatment of postherpetic neuralgia using peppermint oil. The Clin. J. Pain. May/June/2002; 18(3)-200-02.
Friesen KJ, Alessi-Severini S, Chateau D, Falk J, Bugden S 2016. The changing landscape of antiviral treatment of herpes zoster: a 17-year population-based cohort study. ClinicoEconomics and Outcomes Research: CEOR. 8:207-214.
Guidelines on the Treatment of Skin and Oral HIV–Associated Conditions in Children and Adults 2014. Geneva: World Health Organization.
Jeon YH 2015. Herpes Zoster and Postherpetic Neuralgia: Practical Consideration for Prevention and Treatment. Korean J Pain. 28(3):177-84.
Johnson RW, Alvarez-Pasquin MJ, Bijl M, Franco E, Gaillat J, Clara JG et al. 2015. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Therapeutic Advances in Vaccines, 3(4), 109–120.
Marin M, Yawn BP, Hales CM, Wollan PC, Bialek SR, Zhang J, Kurland MJ, Harpaz R 2015. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status. Hum Vaccin Immunother.;11(5):1157-64.
“Matrix é Aqui”. Ser Médico (Cremesp) Jul/Ago/Set/2009; n. 48. p. 14-15.
McCrary ML et al. Varicella Zoster Virus (CME). J. Am. Acad. Dermatology. July/1999; 41(1)-1-16.
Nagasako EM et al. Rash severity in herpes zoster: correlates and relationship to postherpetic neuralgia. June/2002; 46 (6)-834-9.
Oxman MN et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Eng. J. Med. Jun/2005; 352, 2271-84.
Préaud E, Uhart M, Böhm K, Aidelsburger P, Anger D, Bianic F, Largeron N 2015 Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany. Hum Vaccin Immunother.;11(4):884-96.
Rice G et al. Gabapentine in the treatment of postherpetic neuralgia. Pain. 2001; 94-215-24.
Rook A et al. Herpes-zoster. Textbook of dermatology. 4th edition. Blackwell Editions.1986; Vol.1. p. 680-85.
Sampaio S, Rivitti EA. Herpes-zoster. 3. ed. Dermatologia. Artes Médicas. 2007; 560-1.
Shuanglin H et al. Gene transfer of glutamic acid decarboxylase reduces neurophatic pain. Annals of Neurology. June/2005; 57(6) 914-18.
Teixeira MJ et al. Iontoforese de vincristina para o tratamento de neuralgia pós-herpética. Arq. Brasil. de Neuroc. 1993; (12)223-34.
Tseng HF, Liu A, Sy L, Marcy SM, Fireman B, Weintraub E et al. 2012 Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. J Intern Med. 271(5):510-20.
